PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES
www.patentreply.ai/tools/patent-expiration/US9388221Important: This calculator does not include patent term extension under 35 U.S.C. § 156, which may apply to certain drug, biologic, animal drug, and medical device patents.
Learn more about PTE and patent expirationPapillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies
Application No. 13772893
February 1, 2026
Expired 153 days agoEarliest effective filing
Feb 1, 2006
+ 20 years
Feb 1, 2026
PTA +0d
Feb 1, 2026
TD applied
Feb 1, 2026
Final
Feb 1, 2026
Filing Date
February 21, 2013
Earliest Effective Filing
February 1, 2006
Issue Date
July 12, 2016
PTA
0 days
Base Expiry (before PTA)
February 1, 2026
Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies
Filing Date
May 13, 2008
Earliest Effective Filing
Feb 1, 2006
Issue Date
Mar 26, 2013
PTA
+1191 days
Calculated Expiration
May 7, 2029
Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies
Filing Date
Feb 21, 2013
Earliest Effective Filing
Feb 1, 2006
Issue Date
Jul 12, 2016
PTA
0 days
Calculated Expiration
Feb 1, 2026
Mixing Group And Method For Mixing Two Compounds
Filing Date
Oct 3, 2017
Earliest Effective Filing
Apr 15, 2016
Issue Date
Apr 20, 2021
PTA
+462 days
Calculated Expiration
Jul 21, 2037
Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.